Article
Pharmacology & Pharmacy
Taisuke Kaiho, Hidemi Suzuki, Atsushi Hata, Hiroki Matsumoto, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Summary: Immune checkpoint molecules, such as PD-1 and PD-L1, have been shown to be important in lung cancer treatment. This study explored the role of these proteins in acute rejection in a mouse model of tracheal transplantation and found that PD-L1 Fc recombinant protein could decrease inflammatory cytokines and reduce the proportion of CD4+ T cells, suggesting a potential novel target for immunotherapy in lung transplantation.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Medicine, General & Internal
Ying Cheng, Hui Li, Liang Zhang, Jing-Jing Liu, Chang-Liang Yang, Shuang Zhang
Summary: In recent years, immune checkpoint inhibitors have made significant breakthroughs in the treatment of lung cancer, with combination immunotherapy being widely used to improve efficacy. The combination of PD-1/PD-L1 inhibitors with other treatment modalities is a current research focus.
CHINESE MEDICAL JOURNAL
(2021)
Article
Respiratory System
Koichi Miyashita, Masato Karayama, Yusuke Inoue, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Masato Kono, Takashi Matsui, Mitsuru Niwa, Keigo Koda, Mikio Toyoshima, Sayomi Matsushima, Shun Matsuura, Kazuhiro Asada, Masato Fujii, Hideki Kusagaya, Hiroyuki Matsuda, Naoki Inui, Takafumi Suda
Summary: The clinical efficacy of immune checkpoint inhibitors for non-small cell lung cancer with uncommon histology was found to be similar to that for common histology, with ECOG-PS of 0-1 and PD-L1 expression being predictive factors for efficacy of ICIs in rare histological types of NSCLC.
BMC PULMONARY MEDICINE
(2021)
Review
Oncology
Liza C. Villaruz, George R. Blumenschein Jr, Gregory A. Otterson, Ticiana A. Leal
Summary: The development of PD-1/PD-L1 immune checkpoint inhibitors has revolutionized the treatment of advanced and/or metastatic NSCLC. However, many patients do not respond or only have a temporary benefit from these agents. Resistance mechanisms, such as upregulation of immune checkpoints and immunosuppressive tumor microenvironment, need to be overcome to improve patient outcomes. This review discusses novel therapeutic strategies to enhance responses to PD-(L)1 inhibitors and counter resistance in NSCLC, and summarizes the latest clinical evidence.
Article
Pathology
Esther Conde, Susana Hernandez, Amparo Benito, Alejandra Caminoa, Pilar Garrido, Fernando Lopez-Rios
Summary: Standardization of ROS1 testing assays is crucial, and the VENTANA ROS1 (SP384) antibody, with its high sensitivity, is an excellent analytical option for screening ROS1 fusions in patients with advanced non-small cell lung carcinomas.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2021)
Article
Multidisciplinary Sciences
Will Paces, Elliott Ergon, Elizabeth Bueche, G. Dave Young, Vitria Adisetiyo, Cris Luengo, Meredith James, Charles Caldwell, Dannah Miller, Morgan Wambaugh, Geoffrey Metcalf, Roberto Gianani
Summary: PD-L1 (22C3) digital assay can assist in clinical treatment decisions for non-small cell lung cancer (NSCLC) patients, while reducing the complexity and variability among pathologists.
SCIENTIFIC REPORTS
(2022)
Review
Medicine, General & Internal
Chu-Ling Li, Yong Song
Summary: Immunotherapy has greatly impacted the treatment of non-small cell lung cancer, with combination strategies showing promising clinical outcomes. However, there is still room for improvement in response rates, necessitating exploration of alternative combination models and candidate selection strategies.
CHINESE MEDICAL JOURNAL
(2021)
Review
Immunology
Quanqing Tang, Shihao Li, Gaozhen Huang, Hongwei Liu
Summary: Urothelial carcinoma (UC) is a common malignant tumor. Platinum-based chemotherapy has been the standard treatment for metastatic UC, but immune checkpoint inhibitors (ICIs) offer hope for patients unfit for platinum therapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Kazuya Takamochi, Kieko Hara, Takuo Hayashi, Shinji Kohsaka, Fumiyuki Takahashi, Yoshiyuki Suehara, Kenji Suzuki
Summary: This study investigated the associations between PD-L1 expression and clinicopathological features, prognosis, and driver oncogene alterations in 1,005 surgically resected lung adenocarcinoma specimens. The results showed that PD-L1 positivity was more common in male smokers and tumors with specific pathological features. Although PD-L1 positivity was associated with poor survival outcomes, it was not statistically significant in multivariate analysis.
Review
Immunology
Jianqiong Yin, Yuanjun Wu, Xue Yang, Lu Gan, Jianxin Xue
Summary: Immune checkpoint inhibitors (ICIs) are drugs used to treat non-small-cell lung cancer by enhancing the function of T cells and producing long-lasting antitumor effects. However, ICIs can cause immune-related adverse events (irAEs), including severe pneumonia. Currently, the diagnosis and mechanisms of checkpoint inhibitor pneumonitis (CIP) are not well understood.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Marton Gyulai, Zsolt Megyesfalvi, Lilla Reiniger, Tunde Harko, Bence Ferencz, Luca Karsko, Laszlo Agocs, Janos Fillinger, Balazs Dome, Zoltan Szallasi, Judit Moldvay
Summary: This study aimed to assess the potential role of immunotherapy in rare lung tumors. Immunohistochemical staining detected the expression of PD-L1 and PD-1 in mucoepidermoid carcinomas, adenoid cystic carcinomas, and tracheobronchial papillomas. A strong PD-L1 immunopositivity was observed in one mucoepidermoid carcinoma sample, indicating a need for further investigation.
PATHOLOGY & ONCOLOGY RESEARCH
(2023)
Review
Oncology
Wen Wen, Yong Zhang, Hua Zhang, Yingshuang Chen
Summary: PD-L1/PD-1 inhibitors have shown effective and tolerable outcomes in advanced hepatocellular carcinoma patients. Additionally, the combination of PD-L1/PD-1 inhibitors with anti-VEGF agents leads to more clinical improvements compared to monotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Maofen Jiang, Chunjiao Liu, Dongxiao Ding, Hui Tian, Chaoqun Yu
Summary: This study aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer (NSCLC) patients and determine the optimal therapeutic regimen through network meta-analysis. The results showed that atezolizumab, cemiplimab, nivolumab, and pembrolizumab significantly improved overall survival compared to chemotherapy. Additionally, cemiplimab may have the most favorable risk-benefit ratio and ranked first in terms of efficacy and safety.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Topias Karjula, Hanna Elomaa, Anne Niskakangas, Olli Mustonen, Iiris Puro, Teijo Kuopio, Maarit Ahtiainen, Jukka-Pekka Mecklin, Toni T. Seppala, Erkki-Ville Wirta, Eero Sihvo, Juha P. Vayrynen, Fredrik Yannopoulos, Olli Helminen
Summary: The study found that CD3(+) and CD8(+) T-cell density and PD-1/PD-L1 expression have prognostic value in pulmonary metastases of colorectal cancer. T-cell infiltration is higher in pulmonary metastases compared to primary tumors. High CD3(+) and CD8(+) cell density are associated with better survival, while high PD-L1 expression is associated with favorable prognosis.
Review
Biotechnology & Applied Microbiology
Kanako Shinada, Shuji Murakami
Summary: Perioperative therapy for non-small cell lung cancer, particularly neoadjuvant PD-1/PD-L1 blockade therapy, has the potential to improve overall survival and contribute to a breakthrough in cancer immunotherapy. However, there are concerns about its long-term efficacy and the need for adequate biomarkers to monitor patient prognosis. This article provides an overview of recent reports on neoadjuvant PD-1/PD-L1 blockade therapy and discusses the challenges it faces in the future.
ONCOTARGETS AND THERAPY
(2023)
Article
Oncology
Youn-Jin Choi, Ahwon Lee, Tae-Jung Kim, Hyun-Tak Jin, Yong-Bok Seo, Jong-Sup Park, Sung-Jong Lee
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2018)
Article
Multidisciplinary Sciences
Seunghye Yu, Hee-Hyun Choi, Il Won Kim, Tae-Jung Kim
Article
Chemistry, Analytical
Sanghyuk Im, Jonghwan Hyeon, Eunyoung Rha, Janghyeon Lee, Ho-Jin Choi, Yuchae Jung, Tae-Jung Kim
Summary: This study demonstrates how deep learning approaches can be used for automatic classification of diffuse glioma subtypes and grading, improving diagnostic accuracy and showcasing the emerging role of deep learning in pathological diagnosis practice.
Article
Oncology
Ho Jung An, Eunkyung An, Shahrooz Rabizadeh, Wei-Li Liao, Jon Burrows, Todd Hembrough, Jin Hyung Kang, Chan Kwon Park, Tae-Jung Kim
Summary: Therapeutic guidance in NSCLC patients with discordant ALK test results remains challenging. SRM quantitative multiplexed proteomics can detect ALK and other predictive proteins, providing additional information for treatment decision-making and predicting clinical outcomes.
Article
Oncology
Kota Ishioka, Hiroyuki Yasuda, Junko Hamamoto, Hideki Terai, Katsura Emoto, Tae-Jung Kim, Shigemichi Hirose, Takashi Kamatani, Sachiyo Mimaki, Daisuke Arai, Keiko Ohgino, Tetsuo Tani, Keita Masuzawa, Tadashi Manabe, Taro Shinozaki, Akifumi Mitsuishi, Toshiki Ebisudani, Takahiro Fukushima, Mari Ozaki, Shinnosuke Ikemura, Ichiro Kawada, Katsuhiko Naoki, Morio Nakamura, Takashi Ohtsuka, Hisao Asamura, Katsuya Tsuchihara, Yuichiro Hayashi, Ahmed E. Hegab, Susumu S. Kobayashi, Takashi Kohno, Hideo Watanabe, David M. Ornitz, Tomoko Betsuyaku, Kenzo Soejima, Koichi Fukunaga
Summary: In this study, FGF9 was found to play a crucial role in the transdifferentiation of lung adenocarcinoma to small cell lung cancer. The upregulation of FGF9 was confirmed to induce neuroendocrine differentiation in established human lung adenocarcinoma cells, providing direct evidence for FGF9-mediated SCLC transdifferentiation and proposing the FGF9-FGFR axis as a therapeutic target for transdifferentiated SCLC.
Article
Biochemistry & Molecular Biology
Seung-Hye Yu, Manjesh Kumar, Il Won Kim, Jeffrey D. Rimer, Tae-Jung Kim
Summary: The study evaluated the cytotoxicity of different types and compositions of zeolites on human lung fibroblast cells, showing that FAU-S exhibited higher toxicity. Different zeolites also showed significant differences in the formation of phagosomes within cells and gene expression.
Article
Oncology
Won Sang Shim, Kwangil Yim, Tae-Jung Kim, Yeoun Eun Sung, Gyeongyun Lee, Ji Hyung Hong, Sang Hoon Chun, Seoree Kim, Ho Jung An, Sae Jung Na, Jae Jun Kim, Mi Hyoung Moon, Seok Whan Moon, Sungsoo Park, Soon Auck Hong, Yoon Ho Ko
Summary: The study developed a DeepRePath model based on deep learning and multi-scale pathology images to predict recurrence in early-stage lung adenocarcinoma patients. The model demonstrated associations between atypical nuclei, discohesive tumor cells, and tumor necrosis in pathology images showing recurrence. Despite limitations, the model showed potential for predicting recurrence after curative resection of early-stage lung adenocarcinoma.
Article
Oncology
Sue Youn Kim, Tae-Eun Kim, Chan Kwon Park, Hyoung-Kyu Yoon, Young Jo Sa, Hyo Rim Kim, In Sook Woo, Tae-Jung Kim
Summary: The PD-L1 22C3 and SP263 assays show a strong correlation in NSCLC patients, with SP263 demonstrating superior sensitivity to PD-L1 in long-term preserved FFPE blocks and sections.
Article
Chemistry, Multidisciplinary
Youngjae Song, Kyungmin Kang, Inho Kim, Tae-Jung Kim
Summary: Digital pathology provides powerful tools for biomarker discovery, analysis, and translation. However, the clinical adoption of digital pathology has been slow and requires clinical and methodological validation. Digital pathological biomarkers can be used in conjunction with other diagnostic technologies to select the most appropriate patient treatment.
APPLIED SCIENCES-BASEL
(2022)
Article
Environmental Sciences
Uiju Cho, Tae-Eun Kim, Chan Kwon Park, Hyoung-Kyu Yoon, Young Jo Sa, Hyo-Lim Kim, Tae-Jung Kim
Summary: The study aims to investigate if pulmonary airway pathology in coal workers with pneumoconiosis can be used as a biomarker for predicting pulmonary morbidity. The results suggest that the severity of alveolitis and goblet cell hyperplasia are independent prognostic factors for coal workers' pneumoconiosis.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Review
Medicine, General & Internal
Inho Kim, Kyungmin Kang, Youngjae Song, Tae-Jung Kim
Summary: With the recent success of artificial intelligence (AI) in computer vision applications, many pathologists expect AI to assist them in various digital pathology tasks. Advances in deep learning have synergized with AI, enabling image-based diagnosis in the field of digital pathology. Efforts are being made to develop AI-based tools that can save time and eliminate errors for pathologists.
Article
Pathology
Uiju Cho, Tae Jung Kim, Wan Seop Kim, Kyo Young Lee, Hye Kyoung Yoon, Hyun Joo Choi
Summary: Despite the development of educational goals by the Korean Society for Cytopathology, there is a lack of systematic approach to cytopathology education for pathology residents in Korea. This study aimed to gather comprehensive data on the current state of cytopathology education and evaluate education outcomes.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE
(2023)
Review
Biotechnology & Applied Microbiology
Kyungmin Kang, Youngjae Song, Inho Kim, Tae-Jung Kim
Summary: The CRISPR-Cas system has revolutionized genetic engineering due to its simplicity, stability, and precision. It has found applications in various fields, including basic research, medical diagnosis and treatment. This review focuses on medical applications, discussing the latest treatment trends and limitations, with a particular emphasis on CRISPR-based therapies for infectious disease, oncology, and genetic disease, as well as diagnostics, screening, immunotherapy, and cell therapy.
BIOENGINEERING-BASEL
(2022)
Article
Environmental Sciences
Seunghye Yu, Hee-Hyun Choi, Gyeongsin Park, Il Won Kim, Tae-Jung Kim
TOXICOLOGICAL AND ENVIRONMENTAL CHEMISTRY
(2019)
Article
Oncology
Masashi Nishimura, Yoshifumi Kimizuka, Takunori Ogawa, Motohiro Tsuchiya, Yoshiki Kato, Akira Matsukida, Shunya Igarashi, Koki Ito, Yusuke Serizawa, Tomomi Tanigaki, Yuji Fujikura, Yuka Katsurada, Sho Ogata, Akihiko Kawana
Summary: This study reports a case of IgG4-related retroperitoneal fibrosis occurring after chemotherapy. The patient showed improvement after discontinuing immunotherapy and receiving steroid treatment.
Article
Oncology
Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda
Summary: This study aimed to investigate the clinicopathological differences and therapeutic response of NSCLC patients with SDC4::ROS1 fusion to crizotinib. The study found that different ROS1 fusion partners may affect the efficacy of crizotinib and patient prognosis. In addition, higher expression levels of ROS1 and pERK1/2 in tumor cells of case 2 may be related to the therapeutic response and prognosis.
Review
Oncology
Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu
Summary: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Over the past decade, immunotherapy has made progress in the treatment of SCLC, but current immune checkpoint inhibitors have limited benefits for patient survival. Therefore, it is important to explore new targets and develop drugs with novel mechanisms for immunotherapy in SCLC.
Article
Oncology
Kazuto Sugai, Kojiro Nakaoka, Rika Tobita, Shinji Kikuchi, Kei Inoue, Midori Enokido, Moriyuki Kiyoshima
Summary: This article presents a case of multilocular mediastinal cyst leading to the development of thymic cancer. Resection of multilocular anterior mediastinal cysts should be considered due to the challenges in preoperative diagnosis, the potential for coexisting tumors with cysts, and the risk of malignant tumor development.